Search

Even if our patient had experienced no life-threatening reactions to drugs sharing the same or similar excipients contained in all currently available anti-SARS-CoV2 vaccines in Italy, we recommended avoidance of anti-SARS-CoV2 vaccination. Keywords: anti-SARS-CoV2 vaccination; case report; excipients; polyethylene glycol 2000; polysorbate 80 EN anti-SARS-CoV2 vaccination case report excipients polyethylene glycol 2000 polysorbate 80 209 210 2 07/19/22 20220801 NES 220801 Among the anti-SARS-CoV2 vaccines currently used in Italy, polyethylene glycol (PEG) 2000 [H(OCH2CH2)nOH; CAS 25322-68-3] is contained in Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273, and polysorbate 80 (PS80) [C SB 64 sb H SB 124 sb O SB 26 sb ; CAS 9005-65-6] in AstraZeneca AZD1222 and Johnson & Johnson Ad26.COV2.S.1 These two excipients are also contained in several other drugs and in daily topical products and have been reported as sensitizers.2,3 Herein, we report a patient with delayed hypersensitivity to the anti-SARS-CoV2 vaccine excipients PEG2000 and PS80 who experienced in the past two episodes of maculopapular eruptions following the administration of two different drugs, each of which containing the two previously mentioned excipients. A case of delayed allergy to polyethylene glycol 2000 and polysorbate 80 confirmed by patch test: Consequences for anti-SARS-CoV2 vaccination?. [Extracted from the article]